Drug pricing, politics and the cost of doing business in the US

Pfizer has agreed to President Trump's 'Most Favoured Nation' (MFN) drug pricing plan, committing to MFN prices for Medicaid sales and new drug launches in the US, in exchange for a $70 billion investment pledge, US manufacturing commitments, and a three-year tariff exemption. This agreement is viewed as a bellwether, with JPMorgan estimating that extending MFN pricing to European pharmaceutical companies would result in a manageable ~1% sales and ~2% earnings reduction, suggesting that while US margins may level off, widespread sector disruption is unlikely.

Analysis

Pfizer Inc. has established a new precedent in U.S. drug pricing by agreeing to the 'Most Favoured Nation' (MFN) framework, effectively de-risking some of the political uncertainty that has weighed on the pharmaceutical sector. In exchange for a three-year exemption from pharma tariffs, a significant competitive advantage, Pfizer has committed to a $70 billion investment, increased U.S. manufacturing, and the adoption of MFN-level pricing for its Medicaid portfolio and new drug launches. According to JPMorgan, the direct financial impact on European pharmaceutical firms, should they follow suit, is manageable, with an estimated 1% reduction in group sales and a 2% decline in earnings before mitigation. The exposure is not uniform, with Sanofi and GSK facing a more pronounced impact (10-15% of U.S. sales from Medicaid) compared to AstraZeneca, Novartis, and Novo Nordisk (approximately 5%). This deal is viewed as a bellwether, suggesting a shift towards a more predictable pricing environment that, while likely to level-off some U.S. margins, avoids the catastrophic, sector-wide disruption previously feared by investors. The concurrent emergence of direct-to-consumer models, such as Novo Nordisk's discounted Ozempic, is seen as part of a broader, but not immediately damaging, reshaping of drug distribution.

Key Decisions for Investors

• Consider that this deal reduces the tail risk of more severe, sector-wide price controls, potentially justifying a re-evaluation of the regulatory risk discount applied to the pharmaceutical sector.
• Pfizer's first-mover status, securing a three-year tariff exemption, may confer a distinct competitive advantage, warranting an analysis of its valuation relative to peers who may face MFN pricing without similaire concessions.
• Investors should differentiate holdings in European pharma based on U.S. Medicaid exposure, as firms like Sanofi and GSK face a materially larger earnings headwind (10-15% exposure) than peers such as AstraZeneca and Novartis (around 5%).
• Monitor the adoption rate of the MFN framework by other manufacturers and the evolution of direct-to-consumer sales channels, as these will be key indicators of future margin compression and industry structure.